Loading…
KALA BIO, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in KALA.
▼ -100.0% over 5Y.
today you would have $0.07▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 9 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $27.80 | $347.00 | $350.00 | $1,907.50 | $3,025.00 | $16,950.00 | $9,225.00 | $12,225.00 | $46,225.00 | |
| P/S | 21.1x | — | — | — | 19.9x | 7.8x | 65.6x | 22.4x | — | — |
| P/B | 4.2x | 73.9x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| GTBPGT Biopharma, Inc. | $0.30 | 0.1x | 3.8x | — | -113.52% | $13.53M |
| PHIOPhio Pharmaceuticals Corp. | $1.13 | — | 1.0x | — | -113.71% | $13.13M |
| ICUSeaStar Medical Holding Corp | $3.09 | — | 3.1x | — | -356.87% | $13.62M |
| HSCSHeartSciences Inc. | $3.03 |
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Company description provided by Yahoo Finance.
| 3.6x |
| 2.6x |
| 4.1x |
| 5.2x |
| 4.2x |
| 4.6x |
| 1.6x |
| 5.1x |
| EPS | -$165.50 | -$507.50 | -$867.50 | -$1,474.00 | -$5,416.00 | -$4,975.00 | -$6,900.00 | -$6,225.00 | -$9,275.00 |
| Profit margin | -1411.01% | — | — | — | -1151.64% | -1268.73% | -1639.85% | -1553.29% | — | — |
| ROE | -312.29% | -385.65% | -312.29% | -562.35% | -236.23% | -848.64% | -104.33% | -317.75% | -63.57% | -47.07% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 42.7x |
| — |
| -4239.91% |
| $13.65M |
| INTSIntensity Therapeutics Inc | $4.25 | — | 1.4x | — | -195.88% | $13.88M |
| RGNTRegentis Biomaterials Ltd | $2.00 | — | 2.2x | — | — | $14.05M |